Liver transplantation at the Sun Yat-Sen University of Medical Sciences in China.
OBJECTIVE
To summarize the results of liver transplantation for various end-stage liver diseases at the Sun Yat-Sen University of Medical Sciences (SUMS), define the role of liver transplantation in the treatment of hepatocellular carcinoma and fulminant hepatitis B, and assess the efficiency of lamivudine on preventing HBV recurrence.


METHODS
Seventy liver transplants performed at the SUMS between April 1993 and December 2000 were retrospectively analyzed. The main indications for liver transplant were hepatocellular carcinoma (26 cases), liver cirrhosis (21 cases), fulminant hepatitis B (12 cases), sclerosing cholangitis (4 cases) and other terminal liver diseases (7 cases). Lamivudine was used in twelve patients suffering from fulminant hepatitis B. Logistic multivariate regression analysis was applied to determine the risk factors predicting liver transplantation outcomes.


RESULTS
Fifty-four patients survived for more than one month, and 16 patients died within 30 days after orthotopic liver transplantation (OLT). The overall hospital survival rate was 77.1%. The hospital survival rates in the Child's A and B patients were 87.5% and 83.3%, respectively. Those rates were superior to those of the Child's C patients (P < 0.05). The outcome of patients with small hepatocellular carcinoma (HCC) was superior to that of patients with large HCC. Preoperative APACE III scores, the severity of ascites and serum creatine level had independent influence on outcome. Of the patients with fulminant HBV infection, 9 recipients survived for a follow-up period of 2 - 24 months. Treatment with lamivudine monotherapy was both well tolerated and efficacious in patients with fulminant hepatitis B.


CONCLUSIONS
The results indicate that orthotopic liver transplantation could provide long-term cure and palliation for patients with HCC, and that patient selection is extremely important in predicting outcome. The results support the continued application of liver transplantation as a therapeutic modality for various end-stage liver diseases and that lamivudine is an effective and safe monotherapy in OLT for patients with HBV infection.
Huang
Jiefu
J
Transplantation Center, The First Affiliated Hospital of Sun Yat-Sen University of Medical Sciences, Guangzhou 510080, China. Jeffrey@gzsums.edu.cn
He
Xiaoshun
X
Chen
Guihua
G
Zhu
Xiaofeng
X
Lu
Mingqiang
M
Wang
Guodong
G
Fu
Yuyang
Y
Yang
Yang
Y
Guan
Xiangdong
X
D000293:Adolescent; D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D002681:China; D015209:Cholangitis, Sclerosing / Q000401:mortality / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000401:mortality / Q000601:surgery; D006801:Humans; D007223:Infant; D008099:Liver / Q000473:pathology / Q000601:surgery*; D008103:Liver Cirrhosis / Q000401:mortality / Q000601:surgery; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012577:Schools, Medical; D015996:Survival Rate; D016896:Treatment Outcome